Abstract
Radioimmunolocalization for detection or therapy of breast cancer has undergone only limited investigation. Successful targeting of breast tumors with radiolabeled antibodies has awaited the identification of the optimal antigen targets, the appropriate antibodies, as well as the linking chemistry necessary to produce stable radioimmunoconjugates. Radioimmunodetection trials in breast cancer have employed both the intravenous and interstitial administration routes. Sensitivity of intravenously administered immunoconjugates for metastatic disease has ranged from 50-78% in small series of patients 1-3. The antibodies used in these trials were directed against various breast cancer associated antigens including human milk fat globule membrane (HMFG) or breast epithelial mucin and CEA. Excellent sensitivity for primary breast tumors using an antibody directed against TAG-72 has been reported3, but in the same patients,
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R. Rainsbury, The localization of human breast carcinomas by radiolabeled monoclonal antibodies, Br JSurg 71:805 (1984).
P. Riva, G. Moscatelli, G. Paganelli and e. al, Antibody-guided diagnosis: An Italian experience on CEA-expressing tumours, Int J Cancer 2(Suppl):114 (1988).
L. Lamki, A. Buzdar, S. Singletary, M. Rosenblum, V. Bhadkamkar, L. Esparza, D. Podoloff, A. Zukiwski, G. Hortobagyi and J. Murray, Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: A Phase I Study, J Nucl Med 32:1326(1991).
S. DeNardo, K. Warhoe, L. O’Grady, I. Hellstrom, K. Hellstrom, S. Mills, D. Macey, J. Goodnight and G. DeNardo, Radioimmunotherapy for breast cancer: treatment of a patient with 1-131 L6 chimeric monoclonal antibody, Int J. Biol Markers 6: 221 (1991).
R. Ceriani, J. Peterson, J. Lee, R. Moncada and E. Blank, Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule, Somat Cell Genet 9:415 (1983).
J. Peterson, D. Zava, A. Duwe and e. al, Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule, Hybridoma 9: 221 (1990).
R. Ceriani, J. Peterson, E. Blank, C. Chan and R. Cailleau, Development and characterization of breast carcinoma cell lines as in vitro and in vivo models for breast cancer diagnosis and therapy, In Vitro (In press).
R. Ceriani, E. Blank and J. Peterson, Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components, Cancer Res 47:532 (1987).
R. Ceriani, M. Sasaki, D. Orthendahl and L. Kaugman, Localization of human breast tumors grafted in nude mice with a monoclonal antibody directed against a defined cell surface antigen of human mammary epithelial cells, Breast Cancer Res Treat 12:177 (1988).
R. Ceriani and E. Blank, Experimental therapy of human breast tumors with 131 I-labeled monoclonal antibodies prepared against the human milk fat globule, Cancer Res 48:4664 (1988).
R. Gonzalez, D. Dienhart, R. Kasliwal and e. al, A Phase I study of a radiolabeled monoclonal antibody 131 Mc5 in breast cancer, (Submitted for publication).
E. Blank, K. Pant, C Chan, J. Peterson and R. Ceriani, A novel anti-breast epithelial mucin MoAb (BrE-3). Characterization and experimental biodistribution and immunotherapy, Cancer J5:38 (1992).
D. Macey, S. DeNardo, G. DeNardo, J. Goodnight and M. Unger, Uptake of Indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Uptake of Indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma, Am J Phys Imag 3: 1 (1988).
D. Macey, G. DeNardo and S. DeNardo, A Treatment Planning Program for Radioimmunotherapy. In:“ Frontiers of Radiation Therapy and Oncology,” J. Vaeth and J. Meyer, ed., Karger, Basel (1990). pp 123–131.
D. Dienhart, D. Bloedow, C. Hartmann and e. al., A phase I trial of KC-4 monoclonal antibody serotherapy of advanced non-small cell lung and breast cancers: Clinical, pharmacokinetic, and immunologic results., Cancer Res (Accepted for publication).
K. Ryan, R. Dillman, S. DeNardo, G. DeNardo, J. Beauregard, P. Hagan, D. Amox, M. Clutter, K. Burnett, C. Rulot, R. Sobol, I. Abramson, R. Bartholomew, J. Frincke, C. Birdwell, D. Carlo, L. O’Grady and S. Halpern, Breast Cancer Imaging with In-111 human IgM monoclonal antibodies: preliminary studies, Radiology 167: 71 (1988).
R. Rainsbury, J. Westwood, R. Coombes, A. Neville, R. Ott, T. Kalirai, V. McCready and J.-C. Gazet, Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-111, Lancet ii:934 (1983).
R. Mandeville, N. Pateisky, K. Philipp, E. Kubista, F. Dumas and B. Groux, Immunolymphoscintigraphy of axillary lymph node metastases in breast cancer patients using monoclonal antibodies: first clinical findings, Anticancer Res 6:1257 (1986).
K. Kairemo, Immunolymphoscintigraphy with 99m Tc-labeled monoclonal antibody (BW431/26) reacting with carcinoembryonic antigen in breast cancer, Cancer Res (Suppl) 50: 949 (1990).
F. Deland, E. Kim, R. Corgan and e. al, Axillary lymphscintigraphy by radioimmunodetection of carcinoembryonic antigen in breast cancer, J Nucl Med 20:(1979).
F. Deland, E. Kim, D. Goldenberg and e.al, Lymphoscintigraphy with radionuclide-labeled antibodies to carcinoembryonic antigen, Cancer Res 40:2997 (1980).
A. Athanassiou, D. Pectasides, K. Pateniotis and e.al, Immunoscintigraphy with 1311-labelled HMFG2 and HMFG1 F(ab’)2 in the pre-operative detection of clinical and subclinical lymph node metastases in breast cancer patients, Int J Cancer 2(Suppl):89 (1988).
A. Epenetos, S. Mather, M. Granowska and e. al, Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours, Lancet 2: 999 (1982).
B. Fisher, C. Redmond, E. Fisher, M. Bauer, N. Wolmark and e. al, Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation, N Engl J Med 312: 674 (1985).
J. Tjandra, I. Russell, J. Collins, J. Andrews, M. Lictenstein, D. Binns and I. MacKenzie, Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer, Cancer Res 49:1600 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kramer, E.L. et al. (1994). Radioimmunolocalization of Breast Cancer Using BrE-3 Monoclonal Antibody. In: Ceriani, R.L. (eds) Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, vol 353. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2443-4_17
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2443-4_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6038-4
Online ISBN: 978-1-4615-2443-4
eBook Packages: Springer Book Archive